Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Chronic pain treatments more effective when taken together

01.04.2005


People suffering from chronic, debilitating pain caused by nerve damage or disease report better pain relief at lower doses of a combined drug treatment than from either drug administered individually, a new Queen’s study funded by the Canadian Institutes of Health Research (CIHR) shows.



When given a combination of the anti-seizure drug gabapentin and the opioid morphine, patients with two different types of neuropathic pain experienced lower pain intensity than when they received either of the drugs individually. As well, significantly lower doses of gabapentin and morphine were required during combination treatment than during treatment with either drug alone.

“We now have the first clinical evidence that combining these drugs provides better pain relief, with comparable side effects,” says lead researcher Dr. Ian Gilron, Director of Clinical Pain Research for Queen’s Departments of Anesthesiology, and Pharmacology & Toxicology, and an anesthesiologist at Kingston General Hospital. “This new treatment approach has the potential to dramatically improve quality of life for people suffering from neuropathic pain, a condition that has puzzled health care workers for years because it is often experienced in areas of the body which appear uninjured.”


Results of the study are published in the March 31 edition of the New England Journal of Medicine.

Also on the team from Queen’s are Joan Bailey (Anesthesiology), Dongsheng Tu (Mathematics and Statistics), Ronald Holden (Psychology,) Robyn Houlden (Medicine); and from Dalhousie University’s Departments of Medicine and Chemistry, Donald Weaver.

“This is exciting news for the health research community in Canada,” says Dr. Rémi Quirion, Scientific Director of CIHR’s Institute of Neurosciences, Mental Health and Addiction. “It is a great achievement for Dr. Gilron and his team, but most importantly, it is a critical research finding for Canadians whose chronic pain may be eased by this research. Dr. Gilron and his team are a shining example of CIHR-funded researchers taking research knowledge from the bench to the bedside.”

Although the research focused on two specific types of neuropathic pain – diabetic neuropathy and postherpetic neuralgia – the methods used in this trial could be employed in studying other chronic conditions such as cancer, spinal disk disease, and the pain experienced after chemotherapy and mastectomies, Dr. Gilron notes. “The numbers of people affected are staggering, and the impact of the problem is devastating and costly.”

Diabetic neuropathy occurs in diabetes patients who experience a constant, burning pain, often in the soles of their feet, that isn’t associated with obvious tissue injury. It is sometimes accompanied by electrical shooting pains up the foot and into the lower leg.

Postherpetic neuralgia results from a re-activation of the virus that causes chicken pox, and usually develops after someone has a herpes zoster or “shingles” infection in an isolated part of the body. In 10 to 20 per cent of people afflicted with herpes zoster, the pain doesn’t go away after the rash disappears. Instead it continues to be felt as a burning sensation and often makes normal touch excruciatingly painful.

Both conditions are due to nerve damage and/or injury, and are associated with the experience of pain in an apparently uninjured area, Dr. Gilron explains. Most of the current treatments for this condition cause side effects, which limit the drug dosage a person can tolerate.

“What we need to do clinically is to achieve a balance between side effects and pain relief,” says the Queen’s anesthesiologist. “The purpose of this study was to evaluate two different drugs for chronic pain, and to carefully measure both the pain-relieving effects and the side effects.”

The clinical trial compared a combination of morphine and gabapentin to each drug alone, as well as to a placebo, in a group of patients with either diabetic neuropathy or postherpetic neuralgia. All the patients received all four treatments.

The results showed that pain intensity was significantly lower with the combination treatment than with either drug alone, or with the placebo. As well, the team found that significantly lower doses of morphine and gabapentin were taken during the combination treatment than during treatment with either drug alone.

“For a lot of these people the pain is unrelenting and it’s unclear when or if it will improve,” says Dr. Gilron. “This new evidence showing that combination treatment provides better pain relief, with comparable side effects, opens the door to exciting possibilities for chronic pain management.”

The Canadian Institutes of Health Research is the Government of Canada’s premier agency for health research. Its objective is to excel, according to internationally accepted standards of scientific excellence, in the creation of new knowledge and its translation into improved health for Canadians, more effective health services and products and a strengthened Canadian health care system.

Contacts:

Nancy Dorrance, Queen’s News & Media Services, 613.533.2869
Therese Greenwood, Queen’s News & Media Services, 613.533.6907
Janet Weichel, CIHR Communications, 613.941.4563

Nancy Dorrance | EurekAlert!
Further information:
http://www.queensu.ca

More articles from Health and Medicine:

nachricht Second cause of hidden hearing loss identified
20.02.2017 | Michigan Medicine - University of Michigan

nachricht Prospect for more effective treatment of nerve pain
20.02.2017 | Universität Zürich

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

NASA's fermi finds possible dark matter ties in andromeda galaxy

22.02.2017 | Physics and Astronomy

Wintering ducks connect isolated wetlands by dispersing plant seeds

22.02.2017 | Life Sciences

Impacts of mass coral die-off on Indian Ocean reefs revealed

21.02.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>